Viral infections in transplant patients

Molecular Pathology in Clinical Practice

Volumn , Issue , 2007, Pages 425-435

  Ferreira Gonzalez, Andrea ^a   Caliendo, Angela M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954583996     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-33227-7_38     Document Type: Chapter

References (77)

1. Rubin RH. The direct and indirect effects of infection in liver transplantation: Pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis. 2002;22:125-154
2. Ljungman P.Beta-herpesvirus challenges in the transplant recipient. J Infect Dis. 2002;186(suppl 1):S99-S109
3. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect. 2002;44:78-83
4. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis. 2001;3(suppl 2):1-5
5. Aitken C, Barrett-Muir W, Millar C, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol. 1999;37:2804-2807
6. Caliendo AM, Schuurman R, Yen-Lieberman B, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol. 2001;39:1334-1338
7. Caliendo AM, St George K, Allega J, et al. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol. 2002;40:1581-1586
8. Mazzulli T, Drew LW, Yen-Lieberman B, et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol. 1999;37:958-963
9. Gerna G, Baldanti F, Middeldorp JM, et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol. 1999;37:902-911
10. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73:968-973
11. Middeldorp J, Sillekens P, Lunenberg J. Diagnosis of active HCMV infection: The mRNA approach. Organs and Tissue. 2000;2:99-107
12. Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol. 2000;38:768-772
13. Caliendo AM, St George K, Kao SY, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol. 2000;38:2122-2127
14. Patel R, Smith TF, Espy M, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients [comment]. J Infect Dis. 1995;171:1010-1014
15. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 1999;68:1305-1311
16. Ferreira-Gonzalez A, Fisher RA, Weymouth LA, et al. Clinical utility of a quantitative polymerase chain reaction for diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplantation. 1999;68:991-996
17. Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donorrecipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis. 1997;176:1484-1490
18. Oldenburg N, Lam KM, Khan MA, et al. Evaluation of human cytomegalovirus gene expression in thoracic organ transplant recipients using nucleic acid sequence-based amplification. Transplantation. 2000;70:1209-1215
19. Razonable RR, Brown RA, Espy MJ, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-Throughput automated systems. J Clin Microbiol. 2001;39:4472-4476
20. Norris S, Kosar Y, Donaldson N, et al. Cytomegalovirus infection after liver transplantation: Viral load as a guide to treating clinical infection. Transplantation. 2002;74:527-531
21. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003;187:1801-1808
22. Hebart H, Rudolph T, Loeffler J, et al. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:181-187
23. Li H, Dummer JS, Estes WR, et al. Measurement of human cytomegalovirus loads by quantitative real-Time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol. 2003;41:187-191
24. Sia IG, Wilson JA, Groettum CM, et al.Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000;181:717-720
25. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002;186:829-833
26. Fisher RA, Saggi BH, Ferreira-Gonzalez A, et al. Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients. Transplantation. 2002;74:573-576
27. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis. 1999;1:105-114
28. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis. 1995;171:576-583
29. Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis. 1995;172:239-242
30. Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis. 2003;188:32-39
31. Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis. 2000;182:1765-1768
32. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis. 2002;185:162-169
33. Hamprecht K, Eckle T, Prix L, et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: Pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis. 2003;187:139-143
34. Kwak EJ, Vilchez RA, Randhawa P, et al. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis. 2002;35:1081-1087
35. Lin PL, Vats AN, Green M. BK virus infection in renal transplant recipients. Pediatr Transplant. 2001;5:398-405
36. Boubenider S, Hiesse C, Marchand S, et al.Post-Transplantation polyomavirus infections. J Nephrol. 1999;12:24-29
37. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virusassociated nephropathy in children and adults. Transplantation. 2003;75:105-112
38. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-Associated interstitial nephritis in the allograft kidney. Transplantation. 1999;67:103-109
39. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renaltransplant recipients [comment]. N Engl J Med. 2002;347:488-496
40. Limaye AP, Jerome KR, Kuhr CS, et al. Quantitation of BK virus load in serum for the diagnosis of BK virus-Associated nephropathy in renal transplant recipients [comment]. J Infect Dis. 2001;183:1669-1672
41. Ginevri F, De Santis R, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-Allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation. 2003;75:1266-1270
42. Leung AY, Chan M, Tang SC, et al. Real-Time quantitative analysis of polyoma BK viremia and viruria in renal allograft recipients. J Virol Methods. 2002;103:51-56
43. Azzi A, Cesaro S, Laszlo D, et al. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol. 1999;14:79-86
44. Iwamoto S, Azuma E, Hori H, et al. BK virus-Associated fatal renal failure following late-onset hemorrhagic cystitis in an unrelated bone marrow transplantation. Pediatr Hematol Oncol. 2002;19:255-261
45. Leung AY, Suen CK, Lie AK, et al. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98:1971-1978
46. Gretch D. Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business [comment]. Hepatology. 2000; 31:788-789
47. Chan SE, Rosen HR.Outcome and management of hepatitis C in liver transplant recipients. Clin Infect Dis. 2003;37:807-812
48. Wali MH, Heydtmann M, Harrison RF, et al. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl. 2003;9:796-804
49. Alonso O, Loinaz C, Abradelo M, et al. Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999. Transplant Proc. 2003;35:1836-1847
50. Berenguer M.Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(suppl 1):S14-S18
51. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002;8:1000-1006
52. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 2002;8(suppl 1):S7-S13
53. Costes V, Durand L, Pageaux GP, et al. Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients. Relationship with histologic outcome of recurrent hepatitis C. Am J Clin Pathol. 1999;111:252-258
54. Nuovo GJ, Holly A, Wakely P Jr, et al. Correlation of histology, viral load, and in situ viral detection in hepatic biopsies from patients with liver transplants secondary to hepatitis C infection. Hum Pathol. 2002;33:277-284
55. Gigou M, Roque-Afonso AM, Falissard B, et al. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol. 2001;75:11292-11297
56. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999;117:619-625
57. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823-830
58. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia. Hepatology. 1996;24:1041-1046
59. Holmes RD, Sokol RJ. Epstein-Barr virus and post-Transplant lymphoproliferative disease. Pediatr Transplant. 2002;6:456-464
60. Muti G, Cantoni S, Oreste P, et al. Post-Transplant lymphoproliferative disorders: Improved outcome after clinico-pathologically tailored treatment. Haematologica. 2002;87:67-77
61. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc. 1995;27(suppl 1):38-40
62. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis. 1985;152:876-886
63. Matsukura T, Yokoi A, Egawa H, et al. Significance of serial real-Time PCR monitoring of EBV genome load in living donor liver transplantation. Clin Transplant. 2002;16:107-112
64. Merlino C, Cavallo R, Bergallo M, et al. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients. New Microbiol. 2003;26:141-149
65. Orentas RJ, Schauer DWJ, Ellis FW, et al.Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant. 2003;7:305-314
66. Limaye AP, Huang ML, Atienza EE, et al. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders [comment]. J Clin Microbiol. 1999;37:1113-1116
67. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84:972-984
68. Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease [erratum appears in J Clin Microbiol. 2002;40:2316]. J Clin Microbiol. 2002;40:351-358
69. Campe H, Jaeger G, Abou-Ajram C, et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosislike symptoms defines patients at risk to develop post-Transplant lymphoproliferative disease. Pediatr Transplant. 2003;7:46-52
70. Kogan-Liberman D, Burroughs M, Emre S, et al. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: A preliminary experience [comment]. J Pediatr Gastroenterol Nutr. 2001;33:445-449
71. Griffiths PD, Clark DA, Emery VC. Betaherpesviruses in transplant recipients. J Antimicrob Chemother. 2000;45(suppl T3):29-34
72. Boutolleau D, Fernandez C, Andre E, et al. Human herpesvirus (HHV)-6 and HHV-7: Two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 2003;187:179-186
73. Kidd IM, Clark DA, Sabin CA, et al.Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection.Transplantation. 2000;69:2400-2404
74. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation. 2002;73:599-604
75. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, et al. Development of a real-Time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J Virol Methods. 2002;100:27-35
76. Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol. 2000;111:774-781
77. Nitsche A, Muller CW, Radonic A, et al.Human herpesvirus 6A DNA Is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. J Infect Dis. 2001;183:130-133